Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer Protein
Catalog No: MAGEA4-HP005
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and KVLEHVVRV peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &KVLEHVVRV).
Product Details
- Molecular Aliases
- MAGE-A4;
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer is greater than 95% as determined by SEC-HPLC.
Background
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01.
References
- (1) Weon JL, Potts PR. The MAGE protein family and cancer. Curr Opin Cell Biol. 2015 Dec;37:1-8. doi: 10.1016/j.ceb.2015.08.002. Epub 2015 Sep 3. PMID: 26342994; PMCID: PMC4688208. (2) Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, Brenner B, Vadai E, Mor O, Stein A, Lemonnier FA, Tzehoval E, Eisenbach L. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br J Cancer. 2004 Jul 19;91(2):398-407. doi: 10.1038/sj.bjc.6601968. PMID: 15213716; PMCID: PMC2409814. (3) Davari K, Holland T, Prassmayer L, Longinotti G, Ganley KP, Pechilis LJ, Diaconu I, Nambiar PR, Magee MS, Schendel DJ, Sommermeyer D, Ellinger C. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. J Immunother Cancer. 2021 Mar;9(3):e002035. doi: 10.1136/jitc-2020-002035. PMID: 33771892; PMCID: PMC7996660.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.